{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:45:51Z","timestamp":1792111551869,"version":"4.4.0"},"reference-count":85,"publisher":"The Endocrine Society","issue":"11","funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"name":"United States Government"},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The incidental thyroid uptake of radiolabeled ligands used in positron emission tomography\/computed tomography (PET\/CT) targeting cell-surface proteins is observed in up to 6% of all scans. While diffuse thyroid uptake of ligands targeting somatostatin receptor type 2 (SSTR2), prostate-specific membrane antigen (PSMA), fibroblast activation protein (FAPI), or choline is observed in normal thyroid or usually signifies a benign thyroid abnormality, a heterogeneous or focal uptake is associated with malignant lesions in up to 19.7% of patients. The PET\/CTs utilizing these ligands are characterized by decreased diagnostic sensitivity for detection of thyroid cancer metastases compared with cross-sectional imaging or 18-fluorodeoxyglucose PET\/CT but are highly specific for detection of a subset of thyroid cancers characterized by a high target protein expression. Increased uptake of radiolabeled ligands targeting SSTR2, PSMA, FAPI, integrin \u03b1v\u03b23, and minigastrin can be used for patient selection for peptide receptor radionuclide therapy (PRRT). PRRT can be applied in clinical trials and\/or off-label for patients with advanced radioactive iodine\u2013refractory thyroid cancer who have limited treatment options or for medullary thyroid carcinoma of neuroendocrine origin. The PRRT-induced disease control rate approaches 60% and PRRT is well tolerated with limited side effects. Efficacy could be improved with careful patient selection based on the expression of molecular targets and their function, quantified by standard uptake values in diagnostic PET\/CT imaging. Adopting an individualized dosimetry-based approach and synthesizing ligands with better tumor retention and residence time may help optimize treatment response.<\/jats:p>","DOI":"10.1210\/clinem\/dgag310","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:58:57Z","timestamp":1785412737000},"page":"e2417-e2428","source":"Crossref","is-referenced-by-count":0,"title":["Application of theranostics in thyroid cancer management"],"prefix":"10.1210","volume":"111","author":[{"given":"Archana","family":"Sridhar","sequence":"first","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20892 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Behiri","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20892 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8633-4420","authenticated-orcid":false,"given":"Joanna","family":"Klubo-Gwiezdzinska","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20892 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"1","key":"2026101520054641400_dgag310-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"8","key":"2026101520054641400_dgag310-B2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association Management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"issue":"5","key":"2026101520054641400_dgag310-B3","article-title":"Meta-analysis on the prevalence and significance of incidental findings in the thyroid gland using other PET radiopharmaceuticals beyond [(18)F]FDG","volume":"18","author":"Iacovitti","year":"2025","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"1","key":"2026101520054641400_dgag310-B4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.surg.2023.04.064","article-title":"Incidental (68)Ga-DOTATATE uptake in thyroid nodules: is guideline-directed management still appropriate?","volume":"175","author":"Wright","year":"2024","journal-title":"Surgery"},{"issue":"6","key":"2026101520054641400_dgag310-B5","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1089\/thy.2016.0174","article-title":"The Rate and clinical significance of incidental thyroid uptake as detected by Gallium-68 DOTATATE positron emission tomography\/computed tomography","volume":"26","author":"Nockel","year":"2016","journal-title":"Thyroid"},{"issue":"12","key":"2026101520054641400_dgag310-B6","doi-asserted-by":"crossref","DOI":"10.1530\/EC-24-0419","article-title":"Abnormal uptake related to the thyroid gland on somatostatin receptor-targeted PET imaging: reported prevalence and rate of thyroid malignancy and parathyroid adenomas","volume":"13","author":"Sj\u00f6stedt","year":"2024","journal-title":"Endocr Connect"},{"issue":"11","key":"2026101520054641400_dgag310-B7","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/MNM.0000000000001887","article-title":"Significance of incidental thyroid 18 F-fluorocholine uptake in patients with hyperparathyroidism imaged for localizing hyperfunctioning parathyroid glands","volume":"45","author":"Gr\u00fcnig","year":"2024","journal-title":"Nucl Med Commun"},{"issue":"36","key":"2026101520054641400_dgag310-B8","doi-asserted-by":"crossref","first-page":"e39602","DOI":"10.1097\/MD.0000000000039602","article-title":"Risk of malignancy in thyroid nodules with increased 11C-Choline uptake detected incidentally on PET\/CT: a diagnostic accuracy study","volume":"103","author":"Frota Lima","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2026101520054641400_dgag310-B9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-0042-1751031","article-title":"Incidental findings on (18) F-Fluorocholine PET\/CT for parathyroid imaging","volume":"21","author":"Broos","year":"2022","journal-title":"World J Nucl Med"},{"issue":"5","key":"2026101520054641400_dgag310-B10","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1007\/s00330-023-09492-5","article-title":"Incidence of PSMA PET thyroid incidentaloma depends on analysis method and tracer","volume":"33","author":"Donswijk","year":"2023","journal-title":"Eur Radiol"},{"issue":"7","key":"2026101520054641400_dgag310-B11","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1007\/s00259-022-05679-y","article-title":"Retrospective analysis of PSMA PET\/CT thyroid incidental uptake in adults: incidence, diagnosis, and treatment\/outcome in a tertiary cancer referral center and University Medical Center","volume":"49","author":"Piek","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2026101520054641400_dgag310-B12","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1007\/s00259-022-05721-z","article-title":"Non-prostate cancer tumours: incidence on (18)F-DCFPyL PSMA PET\/CT and uptake characteristics in 1445 patients","volume":"49","author":"Perry","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"2026101520054641400_dgag310-B13","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2967\/jnumed.117.190215","article-title":"Detection of synchronous primary malignancies with (68)Ga-labeled prostate-specific membrane antigen PET\/CT in patients with prostate cancer: frequency in 764 patients","volume":"58","author":"Osman","year":"2017","journal-title":"J Nucl Med"},{"issue":"7","key":"2026101520054641400_dgag310-B14","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/MNM.0000000000001563","article-title":"Physiological tracer distribution and benign lesion incidental uptake of Al18F-NOTA-FAPI-04 on PET\/CT imaging","volume":"43","author":"Kou","year":"2022","journal-title":"Nucl Med Commun"},{"key":"2026101520054641400_dgag310-B15","article-title":"Clinical significance of diffusely increased uptake of (68)Ga-FAPI in thyroid gland","volume":"8","author":"Liu","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"2026101520054641400_dgag310-B16","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1158\/1078-0432.CCR-20-3453","article-title":"(177)Lu-DOTA-EB-TATE, a radiolabeled analogue of somatostatin receptor type 2, for the imaging and treatment of thyroid cancer","volume":"27","author":"Thakur","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2026101520054641400_dgag310-B17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s12020-024-03779-3","article-title":"Somatostatin receptor imaging of thyroid tissue and differentiated thyroid cancer using gallium-68-labeled radiotracers-a review of clinical studies","volume":"85","author":"Pishdad","year":"2024","journal-title":"Endocrine"},{"issue":"3","key":"2026101520054641400_dgag310-B18","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s00259-024-06944-y","article-title":"PET\/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [(18)F]SiTATE\u2014first clinical experiences","volume":"52","author":"Kunte","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"2026101520054641400_dgag310-B19","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/RLU.0000000000005366","article-title":"68 Ga-DOTATATE PET\/CT versus 18 F-FDG PET\/CT in TENIS syndrome: a head-to-head comparison with elevated and suppressed TSH levels in papillary thyroid carcinoma-a pilot study","volume":"49","author":"Almeida","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"3","key":"2026101520054641400_dgag310-B20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.eprac.2023.12.008","article-title":"The clinical utility of gallium-68-DOTATATE positron emission tomography scanning in medullary thyroid cancer","volume":"30","author":"Gild","year":"2024","journal-title":"Endocr Pract"},{"issue":"4","key":"2026101520054641400_dgag310-B21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12149-021-01579-7","article-title":"Diagnostic value of [(18)F]Fluorocholine PET\/CT in detection of primary medullary thyroid cancer","volume":"35","author":"Jamsek","year":"2021","journal-title":"Ann Nucl Med"},{"issue":"4","key":"2026101520054641400_dgag310-B22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1089\/thy.2018.0552","article-title":"Role of (18)F-choline positron emission tomography\/computed tomography to detect structural relapse in high-risk differentiated thyroid cancer patients","volume":"29","author":"Piccardo","year":"2019","journal-title":"Thyroid"},{"issue":"3","key":"2026101520054641400_dgag310-B23","article-title":"Potential role of PSMA-targeted PET in thyroid malignant disease: a systematic review","volume":"13","author":"Rizzo","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"8","key":"2026101520054641400_dgag310-B24","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1097\/RLU.0000000000003655","article-title":"Prostate-specific membrane antigen expression in patients with differentiated thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy using 68Ga-PSMA-HBED-CC PET\/CT","volume":"46","author":"Verma","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"4","key":"2026101520054641400_dgag310-B25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1089\/thy.2019.0450","article-title":"(68)Ga-DOTA-RGD(2) positron emission tomography\/computed tomography in radioiodine refractory thyroid cancer: prospective comparison of diagnostic accuracy with (18)F-FDG Positron emission tomography\/computed tomography and evaluation toward potential theranostics","volume":"30","author":"Parihar","year":"2020","journal-title":"Thyroid"},{"issue":"4","key":"2026101520054641400_dgag310-B26","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1089\/thy.2020.0169","article-title":"Targeting integrins with radiolabeled RGD analogues for radiotheranostics of metastatic radioactive iodine nonresponsive thyroid cancer: new avenues in personalized medicine","volume":"30","author":"Klubo-Gwiezdzinska","year":"2020","journal-title":"Thyroid"},{"key":"2026101520054641400_dgag310-B27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.nucmedbio.2020.06.006","article-title":"Role of [(99m)Tc]Tc-Galacto-RGD(2) SPECT\/CT in identifying metastatic differentiated thyroid carcinoma after thyroidectomy and radioactive iodine therapy","volume":"88-89","author":"Xu","year":"2020","journal-title":"Nucl Med Biol"},{"issue":"5","key":"2026101520054641400_dgag310-B28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/MNM.0000000000001828","article-title":"Prospective evaluation of 68 Ga-NODAGA-RGD PET-CT in patients of carcinoma thyroid with thyroglobulin elevated negative radioiodine scintigraphy (TENIS) with a head-to-head comparison with FDG-PET\/CT","volume":"45","author":"Gondhane","year":"2024","journal-title":"Nucl Med Commun"},{"issue":"6","key":"2026101520054641400_dgag310-B29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2967\/jnumed.122.264977","article-title":"Preliminary clinical experience with cholecystokinin-2 receptor PET\/CT using the (68)Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer","volume":"64","author":"von Guggenberg","year":"2023","journal-title":"J Nucl Med"},{"issue":"2","key":"2026101520054641400_dgag310-B30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2967\/jnumed.124.268877","article-title":"Safety, biodistribution, and radiation dosimetry of the (68)Ga-labeled minigastrin analog DOTA-MGS5 in patients with advanced medullary thyroid cancer and other neuroendocrine tumors","volume":"66","author":"von Guggenberg","year":"2025","journal-title":"J Nucl Med"},{"issue":"12","key":"2026101520054641400_dgag310-B31","first-page":"791","article-title":"A novel CCK2\/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study","volume":"128","author":"Erba","year":"2018","journal-title":"Pol Arch Intern Med"},{"issue":"1","key":"2026101520054641400_dgag310-B32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00259-019-04458-6","article-title":"EANM practice guideline for PET\/CT imaging in medullary thyroid carcinoma","volume":"47","author":"Giovanella","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2026101520054641400_dgag310-B33","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-08257-x","article-title":"Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review","volume":"21","author":"Maghsoomi","year":"2021","journal-title":"BMC Cancer"},{"issue":"4","key":"2026101520054641400_dgag310-B34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(24)00364-4","article-title":"The role of the hypothalamic-pituitary-thyroid axis in thyroid cancer","volume":"13","author":"Abaandou","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8632","key":"2026101520054641400_dgag310-B35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(89)91258-0","article-title":"Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin","volume":"1","author":"Krenning","year":"1989","journal-title":"Lancet (London, England)"},{"issue":"5","key":"2026101520054641400_dgag310-B36","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Bodei","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2026101520054641400_dgag310-B37","first-page":"2417","article-title":"Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma","volume":"83","author":"Mato","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026101520054641400_dgag310-B38","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1210\/endo.135.6.7988476","article-title":"Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5)","volume":"135","author":"Patel","year":"1994","journal-title":"Endocrinology"},{"issue":"10","key":"2026101520054641400_dgag310-B39","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1007\/s00259-003-1255-5","article-title":"DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals","volume":"30","author":"Wild","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"2026101520054641400_dgag310-B40","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1021\/jm701618q","article-title":"Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting","volume":"51","author":"Cescato","year":"2008","journal-title":"J Med Chem"},{"issue":"11","key":"2026101520054641400_dgag310-B41","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2967\/jnumed.118.209841","article-title":"Safety, pharmacokinetics, and dosimetry of a long-acting radiolabeled somatostatin analog (177)Lu-DOTA-EB-TATE in patients with advanced metastatic neuroendocrine tumors","volume":"59","author":"Zhang","year":"2018","journal-title":"J Nucl Med"},{"issue":"4","key":"2026101520054641400_dgag310-B42","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.220157","article-title":"A review of theranostics: perspectives on emerging approaches and clinical advancements","volume":"5","author":"Burkett","year":"2023","journal-title":"Radiol Imaging Cancer"},{"key":"2026101520054641400_dgag310-B43","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.896287","article-title":"Peptide receptor radionuclide therapy in thyroid cancer","volume":"13","author":"Gubbi","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026101520054641400_dgag310-B44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.critrevonc.2018.01.001","article-title":"Global comparison of targeted alpha vs targeted beta therapy for cancer: in vitro, in vivo and clinical trials","volume":"123","author":"Marcu","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"2026101520054641400_dgag310-B45","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/RLU.0000000000003110","article-title":"Peptide receptor radionuclide therapy in patients with differentiated thyroid cancer: a meta-analysis","volume":"45","author":"Lee","year":"2020","journal-title":"Clin Nucl Med"},{"issue":"9","key":"2026101520054641400_dgag310-B46","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s12149-025-02090-z","article-title":"Recent advances in theranostics and oncology PET: emerging radionuclides and targets","volume":"39","author":"Watabe","year":"2025","journal-title":"Ann Nucl Med"},{"issue":"1","key":"2026101520054641400_dgag310-B47","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1749-6632.1994.tb17300.x","article-title":"Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history","volume":"733","author":"Krenning","year":"1994","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"2026101520054641400_dgag310-B48","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","article-title":"Phase I study of peptide receptor radionuclide therapy with [in-DTPA]octreotide: the Rotterdam experience","volume":"32","author":"Valkema","year":"2002","journal-title":"Semin Nucl Med"},{"issue":"1","key":"2026101520054641400_dgag310-B49","doi-asserted-by":"crossref","DOI":"10.1186\/s13044-026-00290-x","article-title":"Safety and efficacy of peptide receptor radionuclide therapy for advanced medullary thyroid cancer: a systematic review and meta-analysis","volume":"19","author":"Abdlkadir","year":"2026","journal-title":"Thyroid Res"},{"issue":"22","key":"2026101520054641400_dgag310-B50","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-07-0935","article-title":"Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial","volume":"13","author":"Iten","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026101520054641400_dgag310-B51","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5540-5","article-title":"Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls","volume":"19","author":"Beukhof","year":"2019","journal-title":"BMC Cancer"},{"issue":"3","key":"2026101520054641400_dgag310-B52","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/RLU.0000000000004539","article-title":"Peptide receptor radionuclide therapy in patients with advanced progressive medullary thyroid cancer: efficacy, safety, and survival predictors","volume":"48","author":"Liu","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"1","key":"2026101520054641400_dgag310-B53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ando.2022.08.001","article-title":"Feasibility and therapeutic potential of the 68Ga\/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma","volume":"84","author":"Dadgar","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"issue":"12","key":"2026101520054641400_dgag310-B54","first-page":"e4903","article-title":"Metastatic medullary thyroid cancer: the role of 68Gallium-DOTA-somatostatin analogue PET\/CT and peptide receptor radionuclide therapy","volume":"106","author":"Hayes","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026101520054641400_dgag310-B55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4103\/wjnm.WJNM_21_19","article-title":"Clinical efficacy of (177)Lu-DOTATATE peptide receptor radionuclide therapy in thyroglobulin-elevated negative iodine scintigraphy: a \u201cnot-so-promising\u201d result compared to GEP-NETs","volume":"19","author":"Basu","year":"2020","journal-title":"World J Nucl Med"},{"key":"2026101520054641400_dgag310-B56","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.radonc.2019.09.003","article-title":"(68)Ga-DOTATATE PET\/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours","volume":"141","author":"Sharma","year":"2019","journal-title":"Radiother Oncol"},{"issue":"3","key":"2026101520054641400_dgag310-B57","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2967\/jnumed.118.215848","article-title":"Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients","volume":"60","author":"Zhang","year":"2019","journal-title":"J Nucl Med"},{"issue":"1","key":"2026101520054641400_dgag310-B58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1634\/theoncologist.2020-0165","article-title":"(68) Ga-DOTATATE positron emission tomography-computed tomography quantification predicts response to somatostatin analog therapy in gastroenteropancreatic neuroendocrine tumors","volume":"26","author":"Lee","year":"2021","journal-title":"Oncologist"},{"key":"2026101520054641400_dgag310-B59","article-title":"Case Report: regaining radioiodine uptake following PRRT in radioiodine-refractory thyroid cancer: a new re-differentiation strategy?","volume":"2","author":"Hadad","year":"2022","journal-title":"Front Nucl Med"},{"issue":"8","key":"2026101520054641400_dgag310-B60","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1097\/RLU.0000000000005809","article-title":"Revolutionizing thyroid cancer treatment: restoring radioiodine avidity after PRRT-A case series","volume":"50","author":"Aghaee","year":"2025","journal-title":"Clin Nucl Med"},{"issue":"1","key":"2026101520054641400_dgag310-B61","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1038\/s41598-017-05481-z","article-title":"PSMA expression by microvasculature of thyroid tumors\u2014potential implications for PSMA theranostics","volume":"7","author":"Bychkov","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"2026101520054641400_dgag310-B62","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13550-020-0610-x","article-title":"(68)Ga-PSMA PET\/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with (177)Lu-PSMA-617","volume":"10","author":"de Vries","year":"2020","journal-title":"EJNMMI Res"},{"issue":"22","key":"2026101520054641400_dgag310-B63","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.3390\/cancers13225688","article-title":"Prostate-specific membrane antigen in anaplastic and poorly differentiated thyroid cancer-a new diagnostic and therapeutic target?","volume":"13","author":"W\u00e4chter","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2026101520054641400_dgag310-B64","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","article-title":"Cancer-associated fibroblasts: from basic science to anticancer therapy","volume":"55","author":"Yang","year":"2023","journal-title":"Exp Mol Med"},{"issue":"7","key":"2026101520054641400_dgag310-B65","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s12149-022-01742-8","article-title":"(68)Ga-DOTA-FAPI-04 PET\/CT imaging in radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients","volume":"36","author":"Chen","year":"2022","journal-title":"Ann Nucl Med"},{"issue":"9","key":"2026101520054641400_dgag310-B66","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1470-2045(25)00299-2","article-title":"[(68)Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial","volume":"26","author":"Pabst","year":"2025","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026101520054641400_dgag310-B67","first-page":"65","article-title":"Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study","volume":"32","author":"Ballal","year":"2022","journal-title":"Thyroid"},{"issue":"10","key":"2026101520054641400_dgag310-B68","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/RLU.0000000000004260","article-title":"FAP-targeted radionuclide therapy of advanced radioiodine-refractory differentiated thyroid cancer with multiple cycles of 177 Lu-FAPI-46","volume":"47","author":"Fu","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"23","key":"2026101520054641400_dgag310-B69","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast activation protein-targeted radioligand therapy with 177Lu-EB-FAPI for metastatic radioiodine-refractory thyroid cancer: first-in-human, dose-escalation study","volume":"29","author":"Fu","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2026101520054641400_dgag310-B70","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1089\/thy.2024.0229","article-title":"Long-term outcomes in radioiodine-resistant follicular cell-derived thyroid cancers treated with [(177)Lu]Lu-DOTAGA.FAPi dimer therapy","volume":"35","author":"Ballal","year":"2025","journal-title":"Thyroid"},{"issue":"Suppl 1","key":"2026101520054641400_dgag310-B71","doi-asserted-by":"crossref","first-page":"122s","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50 Suppl 1","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"issue":"6","key":"2026101520054641400_dgag310-B72","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3390\/cancers15061889","article-title":"Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics","volume":"15","author":"Martin","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2026101520054641400_dgag310-B73","doi-asserted-by":"crossref","first-page":"e444","DOI":"10.1097\/RLU.0000000000004164","article-title":"First-in-human experience with 177Lu-DOTAGA.(SA.FAPi)2 therapy in an uncommon case of aggressive medullary thyroid carcinoma clinically mimicking as anaplastic thyroid cancer","volume":"47","author":"Ballal","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"5","key":"2026101520054641400_dgag310-B74","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1097\/RLU.0000000000005728","article-title":"177Lu-FAPI-2286 therapy in a patient with radio-iodine refractory papillary thyroid carcinoma: a favorable clinical and biochemical response","volume":"50","author":"Raeisi","year":"2025","journal-title":"Clin Nucl Med"},{"issue":"9","key":"2026101520054641400_dgag310-B75","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1097\/RLU.0000000000005723","article-title":"Combination therapy with 177 lu-FAPI-2286 and tyrosine kinase inhibitor: a novel approach for treating metastatic medullary thyroid carcinoma","volume":"50","author":"Raeisi","year":"2025","journal-title":"Clin Nucl Med"},{"issue":"11","key":"2026101520054641400_dgag310-B76","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3390\/ph17111556","article-title":"Integrin targeting and beyond: enhancing cancer treatment with dual-targeting RGD (arginine-glycine-aspartate) strategies","volume":"17","author":"Bogdanovi\u0107","year":"2024","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"10","key":"2026101520054641400_dgag310-B77","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1007\/s00259-018-4036-x","article-title":"Novel use of (177)Lu-DOTA-RGD(2) in treatment of (68)Ga-DOTA-RGD(2)-avid lesions in papillary thyroid cancer with TENIS","volume":"45","author":"Parihar","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"2026101520054641400_dgag310-B78","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.4103\/ijmr.IJMR_2377_19","article-title":"Theranostic role of radiolabelled RGD peptide in the treatment of radioiodine-resistant thyroid cancer: a novel agent","volume":"152","author":"Vatsa","year":"2020","journal-title":"Indian J Med Res"},{"issue":"6","key":"2026101520054641400_dgag310-B79","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells SA","year":"2015","journal-title":"Thyroid"},{"issue":"6","key":"2026101520054641400_dgag310-B80","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/bip.10356","article-title":"Cholecystokinin-B (CCK-B)\/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies","volume":"66","author":"B\u00e9h\u00e9","year":"2002","journal-title":"Biopolymers"},{"issue":"41","key":"2026101520054641400_dgag310-B81","doi-asserted-by":"crossref","first-page":"7112","DOI":"10.2174\/0929867327666200625143035","article-title":"Cholecystokinin-2 receptor targeting with radiolabeled peptides: current status and future directions","volume":"27","author":"Klingler","year":"2020","journal-title":"Curr Med Chem"},{"issue":"3","key":"2026101520054641400_dgag310-B82","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s00259-022-05992-6","article-title":"[(111)In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial","volume":"50","author":"Lezaic","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2026101520054641400_dgag310-B83","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13550-024-01101-w","article-title":"In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [(177)Lu]Lu-PP-F11N in humans: the lumed phase 0b study","volume":"14","author":"Rottenburger","year":"2024","journal-title":"EJNMMI Res"},{"issue":"4","key":"2026101520054641400_dgag310-B84","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2967\/jnumed.119.233031","article-title":"Cholecystokinin 2 receptor agonist (177)Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma: results of the Lumed Phase 0a study","volume":"61","author":"Rottenburger","year":"2020","journal-title":"J Nucl Med"},{"issue":"2","key":"2026101520054641400_dgag310-B85","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00259-024-06927-z","article-title":"Preclinical evaluation of (225)Ac-labeled minigastrin analog DOTA-CCK-66 for targeted Alpha therapy","volume":"52","author":"Holzleitner","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag310\/70404732\/dgag310.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/11\/e2417\/70404732\/dgag310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/11\/e2417\/70404732\/dgag310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:06:02Z","timestamp":1792109162000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/11\/e2417\/8747958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":85,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,7,31]]},"published-print":{"date-parts":[[2026,10,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag310","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,7,31]]}}}